159 related articles for article (PubMed ID: 31943048)
1. Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice.
Hamoudi D; Bouredji Z; Marcadet L; Yagita H; Landry LB; Argaw A; Frenette J
Hum Mol Genet; 2020 Feb; 29(3):483-494. PubMed ID: 31943048
[TBL] [Abstract][Full Text] [Related]
2. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
Dufresne SS; Boulanger-Piette A; Bossé S; Argaw A; Hamoudi D; Marcadet L; Gamu D; Fajardo VA; Yagita H; Penninger JM; Russell Tupling A; Frenette J
Acta Neuropathol Commun; 2018 Apr; 6(1):31. PubMed ID: 29699580
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts.
Nakamichi Y; Udagawa N; Kobayashi Y; Nakamura M; Yamamoto Y; Yamashita T; Mizoguchi T; Sato M; Mogi M; Penninger JM; Takahashi N
J Immunol; 2007 Jan; 178(1):192-200. PubMed ID: 17182555
[TBL] [Abstract][Full Text] [Related]
4. [Role of OPG in regulation of bone remodeling].
Nakamichi Y; Udagawa N
Clin Calcium; 2006 Sep; 16(9):1463-68. PubMed ID: 16951469
[TBL] [Abstract][Full Text] [Related]
5. RANKL signaling drives skeletal muscle into the oxidative profile.
Cavalcanti de Araújo PH; Cezine MER; Vulczak A; Vieira LC; Matsuo FS; Remoto JM; Santos ADR; Miyabara EH; Alberici LC; Osako MK
J Bone Miner Res; 2024 Apr; ():. PubMed ID: 38619281
[TBL] [Abstract][Full Text] [Related]
6. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis.
Ho TY; Santora K; Chen JC; Frankshun AL; Bagnell CA
Bone; 2011 Jun; 48(6):1346-53. PubMed ID: 21419242
[TBL] [Abstract][Full Text] [Related]
7. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D; Maalouf NM; Sakhaee K
J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
[TBL] [Abstract][Full Text] [Related]
8. Physiological role of receptor activator nuclear factor-kB (RANK) in denervation-induced muscle atrophy and dysfunction.
Dufresne SS; Boulanger-Piette A; Bossé S; Frenette J
Receptors Clin Investig; 2016 May; 3(2):e13231-e13236. PubMed ID: 27547781
[TBL] [Abstract][Full Text] [Related]
9. An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice.
Hamoudi D; Marcadet L; Piette Boulanger A; Yagita H; Bouredji Z; Argaw A; Frenette J
Hum Mol Genet; 2019 Sep; 28(18):3101-3112. PubMed ID: 31179501
[TBL] [Abstract][Full Text] [Related]
10. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
11. Direct effects of osteoprotegerin on human bone cell metabolism.
Grundt A; Grafe IA; Liegibel U; Sommer U; Nawroth P; Kasperk C
Biochem Biophys Res Commun; 2009 Nov; 389(3):550-5. PubMed ID: 19748486
[TBL] [Abstract][Full Text] [Related]
12. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.
Stolina M; Dwyer D; Ominsky MS; Corbin T; Van G; Bolon B; Sarosi I; McCabe J; Zack DJ; Kostenuik P
J Immunol; 2007 Dec; 179(11):7497-505. PubMed ID: 18025194
[TBL] [Abstract][Full Text] [Related]
13. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice.
Oshiro T; Shiotani A; Shibasaki Y; Sasaki T
Anat Rec; 2002 Apr; 266(4):218-25. PubMed ID: 11920384
[TBL] [Abstract][Full Text] [Related]
14. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
15. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures.
Lee SK; Lorenzo JA
Bone; 2002 Jul; 31(1):252-9. PubMed ID: 12110442
[TBL] [Abstract][Full Text] [Related]
16. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
[TBL] [Abstract][Full Text] [Related]
17. Key roles of the OPG-RANK-RANKL system in bone oncology.
Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
[TBL] [Abstract][Full Text] [Related]
18. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
19. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
20. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
